The Edward P. Evans Center for Myelodysplastic Syndromes (MDS)
The mission of the Edward P. Evans Center for Myelodysplastic Syndromes (MDS) at Columbia University is to foster an all-encompassing approach in studying MDS giving us molecular, cellular genetic and epigenetic insights to develop and test innovative therapies. We will map out how it arises and progresses during transformation to Acute Myeloid Leukemia (AML) by studying the generation and fate of MDS cells in their environment in the bone marrow and during aging. We will generate new epigenetic-based approaches, uncovering insights about MDS cells that will lead to new and more effective therapies. The Edward P. Evans Center for MDS will also develop a strong educational program to recruit and train junior and senior scientists with multidisciplinary expertise that can be leveraged to better understand MDS and develop new treatment options for patients.
We will capitalize on the wealth of the multidisciplinary expertise of the Columbia University Irving Medical Center (CUIMC) faculty in basic, translational and clinical research, our Longitudinal MDS Sample Repository of more than 60,000 samples from thousands of unique MDS patients studied longitudinally and technical Innovation developed by members of our team and others offered at CUIMC, Herbert Irving comprehensive cancer center (HICCC) and cores.
- November 10, 2022
In the last 50 years, the main approaches for treating myelodysplastic syndromes or acute myeloid leukemia have not changed. The Kousteni lab aims to change that.
- August 30, 2022
New awards program supports cutting-edge research dedicated to the study and treatment of MDS, a malignant disease that attacks bone marrow stem cells.
- December 15, 2021
The new Center will build upon the dedicated MDS program at Columbia University, a longstanding program of excellence that has served as a national leader in MDS research.